Addex Therapeutics Ltd's latest marketcap:
As of 07/05/2025, Addex Therapeutics Ltd's market capitalization has reached $7.34 M. According to our data, Addex Therapeutics Ltd is the 41980th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 7.34 M |
| Revenue (ttm) | 278,508 |
| Net Income (ttm) | 9.81 M |
| Shares Out | 98.35 M |
| EPS (ttm) | 0.1 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/11/2025 |
Addex Therapeutics Ltd's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | $7.34 M | 24.05% | 41980 |
| 12/30/2024 | $6.2 M | -15.53% | 40090 |
| 12/29/2023 | $7.34 M | -34.64% | 38336 |
| 12/30/2022 | $11.23 M | -73.95% | 35472 |
| 12/30/2021 | $43.12 M | -28.43% | 28435 |
| 12/30/2020 | $60.25 M | 23609 |
Company Profile
About Addex Therapeutics Ltd
Addex Therapeutics Ltd is a Swiss biopharmaceutical company specializing in the discovery, development, and commercialization of small-molecule therapeutics for central nervous system (CNS) disorders. The company focuses on innovative treatments targeting G-protein coupled receptors and enzymes.
Key Programs & Research
- Dipraglurant – A treatment for Parkinson’s disease levodopa-induced dyskinesia, dystonia, and post-stroke/TBI recovery.
- ADX71149 – An orally active mGlu2 PAM (metabotropic glutamate receptor subtype 2 positive allosteric modulator) for epilepsy.
- GABAB PAM – Investigated for pain, anxiety, overactive bladder, addiction, and substance use disorder.
Strategic Collaborations
- Janssen Pharmaceuticals Inc. – Partnership for mGlu2 PAM compounds targeting CNS diseases.
- Indivior PLC – Research agreement for GABAB PAM compounds in addiction and CNS disorders.
- The Charcot–Marie–Tooth Association – Evaluating GABAB PAM in preclinical CMT1A models.
Company Background
Founded in 2002 and headquartered in Geneva, Switzerland, the company was previously known as Addex Pharmaceuticals Ltd before rebranding to Addex Therapeutics Ltd.
Frequently Asked Questions
-
What is Addex Therapeutics Ltd's (ADXN) current market cap?As of 07/05/2025, Addex Therapeutics Ltd (including the parent company, if applicable) has an estimated market capitalization of $7.34 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Addex Therapeutics Ltd (ADXN) rank globally by market cap?Addex Therapeutics Ltd global market capitalization ranking is approximately 41980 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.